Health

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

Ebola virus and Marburg virus cause serious disease outbreaks with high case fatality rates. We aimed to assess the safety and immunogenicity of two investigational DNA vaccines, one (EBO vaccine) encoding Ebola virus Zaire and Sudan glycoproteins and one (MAR) encoding Marburg virus glycoprotein.

Publication Date: 
18/04/2015
Hannah Kibuuka, Nina M Berkowitz, Monica Millard & et al
Lancet
385
9977
1545–1554
Tags:
Ebola Virus Disease ( Ebola Hemorrhagic Fever), Uganda, Research, Drugs, Africa, Viral Diseases